PTGS2 and carcinoma: Together with our earlier findings that α3β1 promotes COX2 expression in breast cancer cells [11], our current data suggest that α3β1 expression may be a determinant of COX2 expression in human breast cancer, and that COX2-positive carcinomas of various subtypes might be vulnerable to therapeutic strategies that target α3β1.